[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mismatch-repair-gene-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mismatch-repair-gene-mutation":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100627590","liquid-biopsy-and-machine-learning-for-early-colorectal-cancer-adenomas-lynch-cancers-and-residual-disease-detection-100627590",false,"NCT07450612","Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection","BEACON","Inclusion Criteria:\n\n* All individuals included in the study need to have had a colonoscopy at the time of blood sampling.\n* Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Received standard pathological and endoscopic diagnosis and assessment for cohort assignment\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Inflammatory bowel disease",true,"ALL","18 Years",{"count":20,"type":21},1200,"ESTIMATED","OBSERVATIONAL","This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Colorectal Cancer","Adenoma Colon","Adenoma Colon Polyp","Colon Adenoma","Colo-rectal Cancer","Colon Disease","Colon Neoplasm","Lynch Syndrome","Lynch Syndrome I","Lynch Syndrome II","Lynch Syndrome I (Site-specific Colonic Cancer)","LYN Gene Mutation","Mismatch Repair Deficiency","Mismatch Repair Gene Mutation","MLH1 Gene Mutation","MSH2 Gene Mutation","MSH6 Gene Mutation","PMS2 Gene Mutation","EPCAM Gene Mutation","RECRUITING","2026-02-27",{"date":47,"type":48},"2026-03-04","ACTUAL",{"date":50,"type":48},"2024-01-01",{"date":52,"type":21},"2031-08-15",{"name":54,"class":55},"San Raffaele University","OTHER",4,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":65,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":68,"conditions":69,"keywords":76,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100446733","the-genpet-study---an-imaging-study-of-fch-pet-ct-in-men-with-prostate-cancer-and-a-dna-repair-gene-mutation-100446733","NCT05097274","The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.","An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation (GENPET)","GENPET","Inclusion Criteria:\n\n* Confirmed pathogenic germline mutation in any of the following genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2 or ATM.\n* Over the age of 18\n* Diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either:\n\n  * At a new diagnosis\n  * Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy\n  * Patients on active surveillance with a PSA doubling time of 6 months or less\n\nExclusion Criteria:\n\n* Diagnosis of other malignancy (excluding basal cell cancer\u002Fsquamous cell cancer of the skin) within five years of diagnosis\n* Known metastatic prostate cancer, both local and distant\n* Patients who have received any oncological treatment within the last six months\n* Patients on any investigational drug treatment\n* Patients on steroids\n* Known history of inflammatory\u002Finfective diseases (e.g. sarcoidosis, tuberculosis, inflammatory bowel disease)\n* Contraindications to having an MRI using the standard MRI checklist (e.g. pacemakers, aneurysm clips, claustrophobia)","MALE",{"count":67,"type":21},50,"The aim of the study is to determine if PET-CT imaging (using contrast recommended in clinical guidelines) is superior to combined bone scan and MRI\u002FCT of the abdomen \\& pelvis in detecting the increased incidence of metastasis (nodal\u002Fdistant outside the pelvis) in men with prostatic carcinoma with mutations in any of the following germline DNA repair genes BRCA1, BRCA2, MSH2, MSH6, MLH1, PMS2, CHEK2, PALB2, ATM.",[70,71,38,72,73,74,75],"Prostate Cancer","BRCA Mutation","ATM Gene Mutation","HOXB13 Germline Mutation","CHEK2 Gene Mutation","PALB2 Gene Mutation",[77,78],"FCH-PET-CT","PSMA-PET-CT","2025-12-08",{"date":81,"type":48},"2025-12-16",{"date":83,"type":48},"2015-10-15",{"date":85,"type":21},"2032-12-31",{"name":87,"class":55},"Institute of Cancer Research, United Kingdom",1]